Walmart, which has nine stores in Alaska and more than 5,000 nationwide, will no longer be selling mifepristone, a chemical abortion drug that kills unborn babies.

“The financial gain from selling mifepristone is infinitesimal compared to the legal and regulatory risk that choice creates — to say nothing of the lost revenue due to the children who aren’t born as a result,” American Family Association Walker Wildmon noted in a recent column. “Walmart understands political neutrality. Its 2024 rollback of DEI policies was a major step to restoring shareholder trust. Not taking sides in the abortion debate is another.

Additionally, the corporate giant has announced that its employee healthcare coverage will now explicitly exclude so-called “gender transition care” for children.

“Gender reassignment surgery is not considered medically necessary for individuals under the age of 18,” the company’s publicly available benefits book states.

In 2025, Walmart dropped its corporate sponsorship of the Anchorage Pride Parade, which is Alaska’s largest public spectacle of LGBTQAI2+ sexuality.

 Wildmon noted that when companies cover and promote transgender surgeries for minors, they risk brand erosion, reputational damage and mounting legal liabilities.

“We’re only seeing more evidence that the risks are real. In January 2026, a New York jury awarded $2 million in damages in the first detransitioner medical malpractice case to reach a verdict,” he wrote. “That detransitioner was only 16 when the surgery happened. Chances are, we’re only going to see more litigation and escalating risk costs around this issue in the coming years.”

Click here to support the Alaska Watchman.